← Oncology Approval Tracker

FDA DECISION ·

Albumin-bound paclitaxel (Teva)

paclitaxel protein-bound particles · Teva Pharmaceuticals

FDA approvalNew formulationMultiple cancer types
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A 100 mg vial of albumin-bound paclitaxel for labeled previously treated breast cancer, first-line advanced NSCLC with carboplatin, and first-line metastatic pancreatic adenocarcinoma with gemcitabine.

LAMPGEN ANALYSIS

Why it matters

The NDA added a product-specific albumin-bound formulation for multiple established regimens.

What research teams should watch

Verify the albumin-bound formulation, reconstitution and the combination partner appropriate to the indication.

PRIMARY RECORDS

Sources